Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
about
The impact of biologics on health-related quality of life in patients with inflammatory bowel disease.Assessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.Inflammatory bowel disease: a Canadian burden of illness reviewMonoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease.Practical application of anti-TNF therapy for luminal Crohn's disease.Certolizumab pegol in the treatment of Crohn's disease.Antagonists of TNF action: clinical experience and new developments.Monoclonal antibodies based on hybridoma technology.New biologic therapeutics for ulcerative colitis and Crohn's disease.Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials.Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.Therapeutic Targets for Emerging Biologic Therapies in IBD.The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
P2860
Q35026298-17573E45-B80E-4610-B336-396E5C1B68C6Q35186984-12F67B75-2BC6-4D87-8C8F-40497AD64635Q36391797-64F7613E-8311-4B41-BC67-BC924C3DC5B7Q36922576-FF4D3CAC-0533-46D0-8B3F-693158DF25B5Q37485709-ECF66F5E-E26B-4E32-9506-8C72D4C1D637Q37703514-F37EE608-79DF-41B2-B17E-8364B769836AQ37704520-CBE460AB-D021-44D4-A263-72366C37CE9FQ37845327-00B67E6C-E972-45D0-97B2-003416C0A67DQ38085665-03D94D4D-1EA5-4311-A9D3-0F6C60B9935DQ38089191-BC4EA288-49B8-49F4-87A7-2A056B394C92Q38162972-EFFF9D49-20EE-4BAF-AC3F-8D640678994CQ38185687-AF78FA76-1B23-4A92-AE5E-6C29FA4EE8FDQ38236706-49847C9C-269B-4099-889C-3F8EF64F3277Q38248218-565DFB18-D993-43E7-8723-21E75DE52E6AQ38317338-87AB4444-E77C-4265-9229-08C320933CD5Q41934485-AF349686-E28A-4B93-8B24-44505EF67D7AQ43434920-773AA85F-C2FA-4575-87C8-9AAE6CED6DA2Q45839795-D21F10F7-97C4-4FED-A2B1-0479A8BC412FQ48059378-7925B55F-0B26-45C9-90F6-53B3F58622F9Q48106537-863DD5B5-019F-4873-98E1-1DE2FDDE6196Q48711362-EDCF4C48-D4F9-439F-8E5D-2BB22CC925A7Q51584924-4BC3B67E-F6EE-4CD9-8738-97A445EBB0D1
P2860
Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@ast
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@en
type
label
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@ast
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@en
prefLabel
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@ast
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@en
P2093
P2860
P50
P1476
Certolizumab pegol, a monthly ...... ate to severe Crohn's disease.
@en
P2093
CDP870 Crohn's Disease Study Group
Dorothy L Keininger
Liz O'Neil
Stefan Schreiber
P2860
P2888
P304
P356
10.1007/S00384-007-0395-7
P577
2007-12-11T00:00:00Z